The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer

Gynecol Oncol Rep. 2021 Oct 12:38:100880. doi: 10.1016/j.gore.2021.100880. eCollection 2021 Nov.

Abstract

•Ovarian cancer is the most lethal among gynecological cancers.•Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients.•Almost one every three patients treated with carboplatin experiences hypersensitivity reactions.•Patients may experience breakthrough reactions during drug desensitization.•Omalizumab represents a promising new treatment to overcome carboplatin hypersensitivity.

Keywords: Drug desensitization; Hypersensitivity reactions; IgE antibiodies; Omalizumab; Ovarian cancer; Platinum salts.

Publication types

  • Case Reports